The present invention provides method of treating a K-Ras-expressing cancer in a subject comprising administering to the subject a therapeutic amount of prostratin or a prostratin analog, or a salt or isomer thereof. Compositions and kits for treating a K-Rasexpressing cancer in a subject are also provided.

The Regents of the University of California

Targeting K-Ras-mediated signaling pathways and malignancy by prostratin

The present invention provides a method of inhibiting neoplasia and tumor promotion. The method comprises administering to a mammal, particularly a human, in need thereof an effective amount of a 12-deoxyphorbol ester, particularly a 12-deoxyphorbol 13-monoester such as 12-deoxyphorbol 13-acetate (prostratin) and 12-deoxyphorbol 13-phenylacetate (dPP).

The United States of America as represented by the Department of Health

Method of inhibiting neoplasia and tumor promotion

Ester prodrugs of phorbol compounds for the treatment of viral infections, neoplastic diseases, inflammatory reactions, and use as analgesics, wherein the phorbol compounds are derivatized with a -x-o-c(o)-R' group linked to the 6-carbon of the phorbol residue.

Salvia Sciences, Inc.

Ester prodrugs of prostratin and related phorbol compounds

The present disclosure provides analogs and derivatives of phorbol compounds for the treatment of viral infections, neoplastic diseases, inflammatory reactions, and use as analgesics.

prostratin/neoplasms

Targeting K-Ras-mediated signaling pathways and malignancy by prostratin

Method of inhibiting neoplasia and tumor promotion

Ester prodrugs of prostratin and related phorbol compounds

Ester prodrugs of prostratin and related phorbol compounds

Cea mai completă bază de date cu plante medicinale susținută de știință